# Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

> **NCT05985655** · PHASE1,PHASE2 · RECRUITING · sponsor: **Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.** · enrollment: 230 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** GTAEXS617
- **DRUG:** SoC

## Key facts

- **NCT ID:** NCT05985655
- **Lead sponsor:** Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2028-01
- **Final completion:** 2028-05
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05985655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05985655, "Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05985655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*